# Diagnos adds former optical retail leader to advisory board

BROSSARD, Quebec - Diagnos Inc. (TSX Venture: ADK, OTCQB: DGNOF), a company focused on AI-based health issue detection, announced Tuesday that Ed Weiner has joined its Advisory Board. The company’s stock, currently trading at $0.14, has seen challenging market conditions with a -61% return over the past year, according to InvestingPro data.

Weiner, who will work alongside Dr. Tomas J. Philipson, former acting chairman of the White House Council of Economic Advisers, will provide insights on the U.S. optical market.

The new advisor brings significant industry experience, having introduced Ralph Lauren Eyewear and partnered with Walmart to open 400 optical locations. He also founded National Vision Associates, described as one of the largest optical retailers in the United States.

"His deep knowledge of the U.S. optical market will contribute to bring DIAGNOS as one of the main AI driven healthcare solutions among opticians and optometrists across the U.S.," said André Larente, President and CEO of Diagnos.

The company develops AI technology to analyze retina images taken by optometrists. According to VisionWatch data cited in the press release, the U.S. recorded approximately 111 million routine eye exams and 60 million medical eye exams in 2020.

Diagnos recently established a U.S. office in south Florida to support American clients and prospects.

The announcement comes as the company seeks to expand its presence in the U.S. optical healthcare market with its AI-based diagnostic tools for eye-related health issues.

The information in this article is based on a company press release statement.

In other recent news, Diagnos Inc. has announced the opening of its first U.S. office in Fort Lauderdale, Florida. This expansion is part of the company’s strategic plan to engage with potential clients and showcase its AI platform to professionals in the ophthalmic and optometry sectors. Additionally, Diagnos has engaged Allele Capital Partners, LLC for capital markets advisory and social media support, with a trial period starting May 22, 2025, potentially extending for nine months. The collaboration with Allele aims to refine Diagnos’ business strategy and optimize capital market objectives, subject to TSX Venture Exchange approval. Diagnos is also in the process of hiring its first U.S. employees and is working towards securing U.S. FDA certification for updates to its AI-assisted fundus image analysis platform. Furthermore, the company has engaged DS Market Solutions Inc. to maintain an orderly market for its securities, starting April 1, 2025. In board-related news, Mr. Francis Bellido has resigned from the board of directors and his role as chairman of the audit committee as of March 27, 2025. Diagnos continues to focus on leveraging AI technology to enhance diagnostic accuracy and patient outcomes in eye care.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.